Drug sales data analysis for outbreak detection of infectious diseases: a systematic literature review by unknown
RESEARCH ARTICLE Open Access
Drug sales data analysis for outbreak detection of
infectious diseases: a systematic literature review
Mathilde Pivette1,2,3*, Judith E Mueller1,4, Pascal Crépey1,5 and Avner Bar-Hen2
Abstract
Background: This systematic literature review aimed to summarize evidence for the added value of drug sales data
analysis for the surveillance of infectious diseases.
Methods: A search for relevant publications was conducted in Pubmed, Embase, Scopus, Cochrane Library, African
Index Medicus and Lilacs databases. Retrieved studies were evaluated in terms of objectives, diseases studied, data
sources, methodologies and performance for real-time surveillance. Most studies compared drug sales data to
reference surveillance data using correlation measurements or indicators of outbreak detection performance (sensitivity,
specificity, timeliness of the detection).
Results: We screened 3266 articles and included 27 in the review. Most studies focused on acute respiratory and
gastroenteritis infections. Nineteen studies retrospectively compared drug sales data to reference clinical data, and
significant correlations were observed in 17 of them. Four studies found that over-the-counter drug sales preceded
clinical data in terms of incidence increase. Five studies developed and evaluated statistical algorithms for selecting
drug groups to monitor specific diseases. Another three studies developed models to predict incidence increase from
drug sales.
Conclusions: Drug sales data analyses appear to be a useful tool for surveillance of gastrointestinal and respiratory
disease, and OTC drugs have the potential for early outbreak detection. Their utility remains to be investigated for
other diseases, in particular those poorly surveyed.
Keywords: Disease outbreaks, Syndromic surveillance, Drug utilization, Nonprescription drugs, Communicable diseases,
Epidemiology
Background
Since the mid-1990s and the raise of concerns about bio-
terrorism and emerging diseases, non-diagnosis-based
data have increasingly been used for routine disease sur-
veillance and outbreak detection [1]. The CDC defined
“syndromic surveillance” as an investigational approach
where health department staff, assisted by automated data
acquisition and generation of statistical alerts, monitor
disease indicators in real-time or near real-time to detect
outbreaks of disease earlier than would otherwise be pos-
sible with traditional public health methods [2].
In such efforts, different registries have served as data
sources for public health surveillance [1,3], including
data on absenteeism at work or school [4], calls to health
helplines [5,6], emergency department consultations
[7,8], ambulance dispatching [9], or drug sales. Although
unspecific, such data sources can have the advantage
over diagnosis-based surveillance of providing informa-
tion within short delays since the event and in readily
available electronic form for relatively low-cost, while
capturing large parts of the population.
Drug sales data analysis may overcome the limitation
of poor specificity when groups of drugs are exclusively
used for the disease or disease syndrome of interest. Fur-
thermore, drug sales data may earlier capture changing
population health status, as over-the-counter (OTC)
sales and a dense network of pharmacies in most deve-
loped countries make drugs easily accessible to patients
at the earliest appearance of their symptoms.
Despite this potential interest, no state of the art of
drug sales based surveillance is available to date. The
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present systematic literature review therefore summarized
the evidence for an added value of drug sales data for in-
fectious disease surveillance. We limited the scope of the
review to infectious diseases, as they represent a public
health problem for which early and valid signal detection
is of particular concern, in light of potentially rapid emer-
gence and opportunity for control interventions.
Methods
We conducted a literature search from 1975 up to June
2012 to identify relevant peer-reviewed articles regarding
surveillance of infectious diseases based on drug sales
data. PRISMA guidelines were followed in the reporting
of the review [10]. Published articles were searched for on
electronic databases (Pubmed, Embase, Scopus, LILACS,
African Index Medicus, Cochrane Library), using com-
binations of the following key words: (“surveillance” OR
outbreak detection OR warning system) AND (over-
the-counter OR “prescription drugs” OR pharmacy OR
(pharmaceutical OR drug OR medication) sales). The
search was limited to articles in English or French. There
were no limitations on study settings.
To be included in the review, articles had to describe,
test, or review an infectious disease surveillance based on
drug sales data; and be original research that presented
new data and results. We excluded studies that monitored
chronic diseases, as well as prevalence studies whose pur-
pose was not epidemic detection.
One reviewer screened and evaluated the titles and ab-
stracts. Articles were widely included in a first stage.
The full-text review and the final selection of the articles
were made by two reviewers.
We reviewed and described the articles in terms of ob-
jectives, diseases studied, data sources, methodologies,
and performance for real time surveillance. To describe
methods and results, we separated the articles into three
groups based on their main objective: descriptive retro-
spective studies, drug selection studies, and prediction
studies. Outcomes selected to compare drug sales data
to reference surveillance data of the corresponding dis-
ease were correlation measurements (strength and time-
liness of the correlation) and indicators of outbreak
detection performance (sensitivity, i.e. ability to identify
true outbreaks; specificity, i.e. ability to identify true
negative and timeliness of the detection).
Results
We screened a total of 3266 articles, of which 27 were
included in the final review. The search and selection
process is presented in Figure 1.
Studies identified from PUBMED, 
SCOPUS, EMBASE, LILACS, 
AIM, Cochrane Library
Titles and abstracts screened 
N= 3266
Full text articles retrieved and 
assessed for eligibility
N= 110




Articles found in reference list of 
selected articles
N=2
Studies excluded based on title 
and review of abstracts
N= 3156
Articles excluded based on full-
text review (no drug sales data, 
no infectious disease, no outbreak 
detection)
N= 85
Figure 1 Flow chart of study selection process in a systematic review of drug sales data analysis for syndromic surveillance of
infectious diseases.
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Objectives of the studies
Three types of studies were defined: retrospective de-
scriptive studies, drug selection studies and prediction
studies.
Nineteen of the 27 studies were descriptive retrospec-
tive studies assessing the strength of the correlation bet-
ween drug sales and reference surveillance data of the
corresponding disease or evaluating outbreak-detection
performance [11-30]. Five studies used statistical algo-
rithms to select groups of drugs that were closely asso-
ciated with clinical surveillance data of a given disease
and that would be most appropriate for future drug-
sales-based surveillance [21,31-34]. In a third group of
three studies, the authors developed and evaluated sta-
tistical models to predict clinical surveillance data based
on drug sales data [35-37]. Table 1 summarizes the stu-
dies in terms of their general characteristics.
Diseases studied
Most of the studies focused on respiratory illnesses (17
studies) [12,14,15,18,20-22,27-32,34-37] or gastrointestinal
illnesses (11 studies) [14,16-19,23-26,32,33]. Only two
other studies evaluated surveillance of pertussis [11] and
syphilis [13].
Populations surveyed
Most of the studies were set in the United States (n = 16
studies, 59%), followed by Canada (n = 4), France (n = 3),
Japan (n = 3), the Netherlands (n = 1) and England (n = 1).
Only one study was conducted in more than one
country [25].
Drug sales data sources
In most retrospective studies, data were collected spe-
cifically for the purpose of the study from a sample of
pharmacies [16,24-26] or from retailers [13,15,17,29].
For example, in a Canadian study [17], electronic data
were provided by one major retailer for all of their 19
pharmacies in the study area.
Automatically compiled data sources were used in all
the drug selection and prediction studies and in some
retrospective studies. Drug sales data were routinely col-
lected in samples of a city’s or country’s pharmacies.
Such routine data collection systems were mainly imple-
mented by research or public health groups, such as the
Johns Hopkins Applied Physics Laboratory [20,21,35,36],
the New York City Department of Health [14], the
National Institute of Infectious Diseases in Japan [27],
or the Real-Time Outbreak and Disease Surveillance
Laboratory at the University of Pittsburg [19]. Data are
available the day after the day’s sales in those systems. In
eight other studies, private marketing companies had
automatically aggregated and made available drug sales
data from a sample (2–90%) of pharmacies in a given
city or country [18,22,23,31-34,37].
Methods and results by study types
Retrospective studies
Nineteen studies retrospectively compared drug sales
data to gold standard reference data of the disease. De-
tails are given in Table 2.
Reference data of the disease included medical case re-
ports [20-22], diagnostic registries of microbiological la-
boratories [16,24,28,29], hospital admission or discharge
data [18-22,27], or clinical emergency department data
[14-16]. The selection of indicator drugs in these studies
was based on the literature or expert opinion. For ex-
ample, Edge et al. [17] selected all anti-nauseant and
antidiarrheal OTC drugs for gastrointestinal surveillance.
In Stirling et al. [26], pharmacists determined which
common antidiarrheal drugs they would report.
Two methods were commonly used to compare drug-
sale and diagnostic data time series: correlation analysis
and signal detection comparison (Table 2). Ten studies
used cross-correlation function to measure the similarity
of two curves and to determine the time lag at which
the correlation between the datasets is maximized.
Cross-correlation is a standard method to determine the
time delay between two signals. In three studies, only
correlation between the time series was examined with-
out analyzing time-lagged relationship. Six studies used
aberration detection methods to evaluate whether and
by how long the date of signal detection by drug sales
precedes the signal based on diagnostic data. The signal
definition for aberration detection was based on either a
simple threshold to define alerts [15] or more complex
algorithms such as the Serfling method [14], ARIMA
models [19], the simple moving average method (MA),
the cumulative sum method (CUSUM) [11,16], or the
exponentially weighted moving average (EWMA) [18].
These studies assessed the performance in terms of
sensitivity, specificity and timeliness of disease outbreak
detection. Five other studies [13,24-26,29] only evaluated
whether drug sales showed a significant increase during
a known epidemic period.
Twelve of 14 studies evaluating OTC sales retros-
pectively found significant correlations or a significant
increase in drug sales [14-18,20-22,24-26,29]. Only two
studies didn’t found any consistent correlation. For ex-
ample, Das et al. [14] found a poor correlation between
OTC antidiarrheal drug sales and emergency department
visits for diarrhea in New York City, with an r2 of 0.24.
They found however an increase in sales during a known
outbreak of norovirus. OTC drug sales preceded clinical
data in three of eight studies that analyzed timeline
correlations [18,20,21]. For example, in Hogan et al.
[18], the correlation coefficient between electrolyte sales
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Table 1 General characteristics of studies included in a literature review of drug sales data analyses for surveillance of infectious diseases
Author Study period Location Syndrome Drug data sources Drug status Time scale
RETROSPECTIVE STUDIES




Polgreen et al. [23] 2011 Jan 1999– Sept 2007 Ohio, USA GI IMS Health’s Xponent database
(Data from retail pharmacies,
covering 70% of all prescriptions)
Prescribed Month




Kirian et al. [19] 2010 July 2003–Dec 2007 San Francisco Bay area GI Sales available through the
National Retail Data Monitor in
three San Francisco Bay Area
counties (number of stores
reporting per week: 592–837)
OTC Week




Van den Wijngaard et al.
[28] 2008
2001–2003 The Netherlands ILI Foundation for pharmaceutical
statistics (85% of Dutch
pharmacies) (13,8 million people)
Prescribed Week
Edge et al. [17] 2006 Jan 2001–April 2004 Canada (one province) GI One major retailer with 19
locations (12% of the pharmacies
in the region)
OTC Week
Das et al. [14] 2005 Aug 2002–March 2005 New York City ILI and GI New York City Department of
Health (248 NYC pharmacies,
30% of citywide sales)
OTC Day
Okhusa et al. [22] 2005 Nov 2003–April 2004 Japan ILI Private marketing company (1100
pharmacies, 2% of the
pharmacies in Japan)
OTC Day
Chen et al. [11] 2005 March 2003–July 2004 A rural county in New York State Pertussis Medicaid database
reimbursement
Prescribed Day





GI One pharmacy in Battleford, one
pharmacy in Walkerton
OTC Week
Magruder et al. [21] 2004 2001–2003 Maryland-Washington-Virginia ILI Johns Hopkins Applied Physics






















Table 1 General characteristics of studies included in a literature review of drug sales data analyses for surveillance of infectious diseases (Continued)
Couturier et al. [13] 2004 2001–2003 Paris and five french regions Syphilis A centralized wholesaler
supplying all French private
pharmacies
Prescribed Month
Hogan et al. [18] 2003 1998–2001 Pennsylvania, Indiana, Utah ILI and GI Information Resources, Inc.,
private company (90% market
share in all the region)
OTC Week
Magruder [20] 2003 2001–2002 Maryland-Washington-Virginia ILI Johns Hopkins APL (300
drugstores in the Maryland-
Washington-Virginia area)
OTC Day
Davies et al. [15] 2003 1998/1999, 1999/2000, 2000/
2001
Nottingham city ILI Retailers (Boots the chemist, 30%
of market share) in the hospital
area, and a pharmaceutical
company (Reckitt Benckiser) at
national level
OTC Week
Stirling et al. [26] 2001 Jan–May 2001 North Battleford, Saskatchewan GI Three pharmacies OTC Week
Proctor et al. [24] 1998 1993 Milwaukee (Wisconsin, USA) GI One pharmacy OTC Day





Cranbrook (British Colombia), Las
Vegas(Nevada)
GI One pharmacy in Milwaukee, 3
pharmacies in Collingwood, 10
to 12 pharmacies in Kelowna and
Cranbrook.
OTC Month
Welliver et al. [29] 1979 1976/1977 Los Angeles ILI One large supermarket chain OTC Week
DRUG SELECTION STUDIES
Pelat et al. [33] 2010 2000-2009 France GI IMS Health (7,500 pharmacies in
2000–13,300 in 2008, 59% of the
pharmacies in France, covering
all continental France)
OTC and prescribed Week
Cami et al. [31] 2009 Jul 2003- Dec 2006 Region around the city of
Houston, TX, USA
ILI AC Nielsen Corp (pharmacy sales
in a region around Houston)
OTC Week
Wallstrom et al. [34] 2007 2002-2004 Pennsylvania, USA ILI AC Nielsen Corp (pharmacy sales
in western Pennsylvania)
OTC Week
Li et al. [32] 2005 Jan 1998- Dec 2001 Pennsylvania, USA ILI and GI Information Resources, Inc.,
private company (90% market
share in the region)
OTC Week
Magruder et al. [21] 2004 2001-2003 Maryland-Washington-Virginia ILI Johns Hopkins APL (300





















Table 1 General characteristics of studies included in a literature review of drug sales data analyses for surveillance of infectious diseases (Continued)
PREDICTION STUDIES
Vergu et al. [37] 2006 2000-2004 France ILI IMS Health (11,000 pharmacies,
50% of all pharmacies in France)
OTC and prescribed Week
Najmi et al. [36] 2005 2001-2003 Maryland-Washington-Virginia ILI Johns Hopkins APL (300
drugstores in the Maryland-
Washington-Virginia area)
OTC Day
Najmi et al. [35] 2004 2001-2002 Maryland-Washington-Virginia ILI Johns Hopkins APL (300
drugstores in the Maryland-
Washington-Virginia area)
OTC Day



















Table 2 Methodology and results of the retrospective studies included in a literature review of drug sales data analyses for surveillance of infectious diseases












STUDIES ON PRESCRIBED DRUGS
Sugawara et al.
[27] 2012








Correlation Pearson corr. coeff.
r = 0.992 for 2009/10 and
r = 0.972 for 2010/11
(p < 0.001)













- - - -
Chopra et al.
[12] 2011




Oseltamivir Correlation Spearman corr.coeff.
r = 0.46 (p < 0.003) Peaks
occurred at the same
time






























r = 0.60 for Influenza A, r
= 0.58 for RSV, r = 0.60 for
S. pneumonia, r = 0.39 for
influenza B (p < 0.05) 80%
of variation explained by
respiratory pathogens
2 weeks earlier
until 1 week later
- - -






































increase in Paris, +10% in
the 5 regions)
Similar trend - - -















between sales and GI
cases counts, outbreak
counts.





































No delay - - -
Okhusa et al.
[22] 2005



































r2 = 0.60 (p < 0.001)






















r2 = 0.24 (p < 0.005)
Similar increases during
the fall (norovirus) and
influenza peak. Increase in
ED GI visits during late
winter (rotavirus), but no
increase in drug sales.
- Less sensitive than
ED system
- -















visits for acute GI,








































Cross-correlation Seasonal trend: Pearson r
(between 0.95 and 0.99)
1- 3 week lead - - -
Non-seasonal trend:






















































































National and local sales
positively correlated with











































A fivefold increase in
sales during the epidemic
period




















































fold; Las Vegas: no data;
Collingwood: increased in
2 of 3 stores;Kelowna:
increased 3 fold;
Cranbrook: increased
- - - -
Welliver et al.
[29] 1979









Sales of cold remedies
averaged 185% above the
baseline value during the
peak influenza activity
- - - -
Abbreviations: ILI Influenza-like illness, GI Gastrointestinal, RSV Respiratory syncytial virus, ATC Anatomical Therapeutic Chemical classification system, CUSUM Cumulative sum control chart, OTC Over-the-counter drugs,



















and hospital diagnoses of respiratory and diarrheal ill-
ness was 0.90 (95% CI, 0.87–0.93) when drug sales were
assumed to precede clinical diagnosis data by 1.7 weeks.
Outbreaks were detected with 100% sensitivity and spe-
cificity in 3 of 5 studies that analyzed signal detection
[15,16,18]. Drug sales data provided an earlier outbreak
signal in two of them [15,18]. In Davies et al. [15], the
rate of cough/cold sales exceeded a threshold of 1000
units per week two weeks before the peak in emergency
department admissions during three consecutive winters.
In Hogan et al. [18], detection from electrolytes sales oc-
curred an average 2,4 weeks earlier than detection from
hospital diagnoses of respiratory and diarrheal diseases.
Six of the seven studies that focused on prescribed
drugs found strong correlations (r = 0.46–0.99) with clin-
ical reference data or a significant increase in drug sales,
without lead time however. The other study [11] showed
that the CUSUM signal generated for prescriptions for
macrolide antibiotics was linked to a pertussis outbreak
in a county of New York State.
No association was observed between the type of refe-
rence data and the time lags observed.
Drug selection studies
An important challenge for drug-sales-based surveillance
is identifying relevant indicator drug groups to monitor
diseases. Five retrieved articles addressed this question.
Characteristics of the studies are described in Table 3.
Two studies [21,34] developed methods to find homo-
geneous groups of OTC products. The authors used
unsupervised clustering algorithms for aggregating OTC
products in groups sharing similar sales histories. For
example, Magruder et al. [21] first assigned OTC products
for respiratory diseases to subgroups qualitatively based
on indication, dose form, and age group. A stepwise
hierarchical clustering algorithm was then used to form
categories sharing a similar sales history, leading to a set
of 16 product categories.
In two studies [31,33], the authors developed proce-
dures to identify the drugs correlating with disease inci-
dence. Clusters were formed specifically for a particular
disease. In Pelat et al. [33], a hierarchical clustering pro-
cedure was applied to the time series of all therapeutic
classes and the acute diarrhea incidence rate reported by
a network of general practitioners. Four therapeutic clas-
ses were found to cluster with diarrhea incidence and an
algorithm based on the selected drugs allowed the de-
tection of epidemics with a sensibility of 100%, a specifi-
city of 95% and a timeliness of 1.7 weeks before official
alerts.
Prediction studies
In three studies [35-37], the authors developed models
to predict clinical data based on drug sales data.
Vergu et al. [37] used a Poisson regression model on
selected OTC sales to forecast influenza-like illness (ILI)
incidence as recorded by a sentinel network of general
practitioners. The forecast at the national level 1–3
weeks ahead showed a strong correlation with observed
ILI incidence (r = 0.85–0.96).
Najmi et al. [35] used least mean square filtering
methods to estimate the incidence of emergency room
consultations for respiratory conditions from past and
present sales of groups of cold-remedy sales. In a later
article [36], they succeeded in extending the estimation
algorithm for predicting increases in clinical data several
days in advance.
Discussion
The evidence gathered in this systematic literature review
suggests that drug sales data analysis can be a useful tool
Table 3 Methodology and results of drug selection studies included in a literature review of drug sales data analysis
for surveillance of infectious diseases
Author Disease Method Results of the algorithm evaluation
Pelat et al. [33] 2010 GI Hierarchical clustering procedure ,CUSUM Identification of 4 therapeutic classes relevant to gastroenteritis
outbreak detection. Detection performance of a multiple voter
algorithm: sensibility 100%, specificity 95%, timeliness
1.7 weeks.
Cami et al. [31] 2009 ILI Aggregate mining algorithm Identification of product categories with outbreak detection
performance superior to predefined categories and more
strongly correlated with the disease data.
Wallstrom et al. [34] 2007 ILI Unsupervised time-series clustering algorithm Distinction between OTC products for allergy and OTC
products for influenza symptoms
Li et al. [32] 2005 ILI/GI Canonical correlation analysis Identification of eight diagnoses that have strong association
with electrolyte sales (r = 0.96)
Magruder et al. [21] 2004 ILI Unsupervised stepwise clustering algorithm Identification of 16 OTC product groups with similar historical
trends
Abbreviations: GI Gastrointestinal, CUSUM Cumulative sum control chart, ILI Influenza-like illness, OTC Over-the-counter drugs.
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for surveillance of acute respiratory and gastrointestinal
infections.
As could be expected, prescribed drug sales data were
strongly correlated with clinical case reporting. No lead
time was observed, which is consistent with the fact that
patients purchase drugs after seeing a healthcare profes-
sional. Analysis of prescribed drug sales data may never-
theless have an additional utility for epidemic detection,
as these data might be available with a shorter delay
than clinical surveillance data [27].
A high correlation between OTC drug sales data and
reference surveillance data were found in almost all the
retrospective studies. Several studies also showed that
OTC drug sales can serve as an early indicator of disease
epidemics. Patients may buy nonprescription drugs du-
ring the early phase of illness when they become symp-
tomatic, before consulting a health practitioner [38]. A
surveillance system based on drug data should ideally
detect all the outbreaks, rapidly, with a low false alert
rate. However, few studies in the review determined the
sensitivity and specificity of the outbreak detection and
those aspects should be analyzed in more details in fu-
ture studies.
Surveillance based on OTC drug sales could be par-
ticularly relevant for diseases whose prodromal phase
persists for several days before the onset of more severe
symptoms. For example, the early stages of dengue fever
symptoms are nonspecific (fever, headache, myalgia,
arthralgia, etc.) [39]. The occurrence of grouped cases
could trigger an excess of nonspecific drug sales over
baseline levels, which in turn could provide an early
warning of outbreak in an endemic area.
Results from drug selection studies showed that it is
possible to identify groups of products strongly associated
with incidence data, which can then be used to predict fu-
ture trends in clinical data and help public health author-
ities to prepare response planning. Such product selection
procedures, however, depend on the existence of large
clinical surveillance databases of the diseases concerned.
Similarly, the validity of drug sales data analysis has
been evaluated mainly for two disease groups, respiratory
and gastrointestinal illness, for which clinical reference
data, used as the gold standard, are readily available. Per-
tussis and syphilis have been evaluated in only one study
each, and still require further confirmation. The concept
of drug-based surveillance therefore needs to be validated
for other infectious diseases.
All the studies were conducted in developed countries
or area. Surveillance based on drug sales data requires
electronic information systems for routine data analysis.
Besides, its implementation requires that the population
has access to the health care system and mainly buy drugs
in pharmacies. This could limit the use of drug based sur-
veillance systems in developing countries.
By improving the timeliness of epidemic detection
compared to clinical data and giving information from a
larger part of the population, drug sales data can be an
additional source of information for already monitored
diseases. Besides, drug sales data analysis could have its
greatest value in the surveillance of diseases for which
clinical surveillance is cumbersome and costly, or where
substantial under-reporting is suspected. To confirm the
selected drug group as a valid proxy of disease, clinical
surveillance may be conducted for a defined period in
a representative population. Examples of diseases for
which this would be useful are typically varicella, urinary
infections, allergies/asthma, and parasitic diseases.
Ideally, the drugs to be monitored should be specific
to the disease and widely used to treat it in order to
maximize the sensitivity of the signal. For example, ben-
zylpenicillin benzathine 2.4 MUI is the quasi exclusive
treatment for syphilis infection [13] and is a good candi-
date. In contrast, the treatment of measles is mostly
symptomatic without a specific drug, which makes this
disease unattractive for this approach. Another limita-
tion applies to diseases that are usually treated in hospi-
tals or specialized centers, such as tuberculosis.
Surveillance based on drug sales, may not be appropri-
ate to accurately estimate incidence of diseases, as the
source population size is not precisely known. Moreover,
it may be difficult to link the number of drug packages
sold to the number of patients with disease. However, the
method is very efficient to determine temporal dynamics
of a situation and to detect abnormal phenomena. Sur-
veillance based on drug sales is therefore well adapted to
diseases with seasonal variations such as norovirus gastro-
enteritis, influenza and other infectious respiratory agents,
or community outbreaks (foodborne illnesses, waterborne
illnesses, hepatitis A, etc.).
Drug sales can be influenced by store promotions,
sales period (holidays, weekends), and the media. Also,
we do not know whether people buy medications to
treat a disease they currently have or a disease they fear
they may have in the near future. For example, during
the media coverage of avian influenza A (H5N1) in the
US, an increase in antiviral medications sales was ob-
served [40], which corresponded to stockpiling behavior
of the population.
Health-seeking behaviors also vary by demographic, so-
cial, cultural, and economic factors. A survey [41] in
Canada analyzed the healthcare-seeking behaviors of 351
patients with acute gastroenteritis. They found significant
differences (patient age and sex) between the patients who
used OTC drugs and those who did not. Consequently,
factors that prompt self-medication should also be taken
into account. The usefulness of drug sales based surveil-
lance is also dependent on the available resources and the
organization of the health care system. OTC drug sales
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surveillance is for example less relevant in countries where
reimbursement rate are high and patients mainly get pre-
scribed drugs.
Population mobility, particularly in tourist areas, may
lead to an increase in remedy sales, which could wrongly
be interpreted as a disease outbreak. Inversely, patients
with high geographical mobility may not be included in
the region of study and lead to an underestimation of
the magnitude of an epidemic.
Despite some limitations, routine collection and analysis
of drug sales data are likely to be developed in the coming
years. Many automated surveillance systems that collect
drug data the day after the sales have been implemented
in the last decade [14,19,20,27]. They allow a rapid assess-
ment of the public health situation. Early detection of out-
breaks allows public health authorities to set up epidemic
investigations and control measures sooner. Most studies
included in this review were published after the year 2000,
with their number increasing recently. They illustrate the
need for improved surveillance systems, evidenced by re-
cent public health crises (e.g., anthrax in 2001, the SARS
outbreak in 2003, the A/H1N1 influenza pandemic in
2009, etc.). Drug sales data present indeed many advan-
tages in terms of public health surveillance. Data can be
obtained in a real-time manner and usually cover a large
portion of the population. Data collection may be exhaust-
ive, without selection of specific sales, and allows the sim-
ultaneous monitoring of a large number of diseases,
especially new or emerging diseases.
Although non-specific, drug sales data are directly
linked to patients’ health conditions. Drug sales data are
therefore more specific than other syndromic surveil-
lance data, such as tracking search patterns on the web
and are likely to reflect more accurately disease activity
in the population. Moreover, it should be noted that al-
ternative sources of data for disease surveillance are cur-
rently under development. Healthcare management
databases that can provide exhaustive information on
drug consumption and diagnosis, as the Dossier Médical
Personnel [42] in France, are promising tools for disease
surveillance.
Our review may be affected by a publication bias since
studies unable to show correlations between drug sales
and reference data may have been less published. In
addition, selections bias may have occurred in the stud-
ies. Indeed, some studies in the review were based on a
limited number of pharmacies and/or a limited study
period (e.g. less than one year). Language bias may exist
as we were not able to identify studies published in lan-
guages other than English and French. The review fo-
cused on the temporal dynamics of infectious disease;
consequently, further analyses are required to determine
the capacity of these systems to efficiently monitor other
aspects of infectious diseases such as spatial spreading.
Conclusion
This review suggests that the analysis of drug sales data is
a promising method for surveillance and outbreak detec-
tion of infectious diseases. It has the potential to trigger
an outbreak alert earlier than most surveillance systems.
However, the main challenges consist in the appropriate
selection of indicator drug groups and the validation of
this approach for diseases for which no or poor quality
clinical surveillance data exists. The usefulness of the ap-
proach also depends on the available resources and the
organization of the health care system. Drug sales data-
bases with real-time or near real-time data transmission
are available in several countries; future studies should be
encouraged to expand their use on other infectious
diseases.
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